Navigation Links
MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009

VALENCIA, Calif., April 27 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) will release its 2009 first quarter financial results on Monday, May 4, 2009.

Management of the Company will host a conference call to discuss the first quarter financial results and other Company developments at 4:00 PM EDT on May 4, 2009. Presenting from the Company will be its Chairman and Chief Executive Officer, Alfred Mann; President and Chief Operating Officer, Hakan Edstrom; Corporate Vice President and Chief Financial Officer, Matthew Pfeffer and Corporate Vice President and Chief Scientific Officer, Peter Richardson.

To participate in the live call by telephone, please dial (888) 677-5721 or (210) 839-8507. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at

A telephone replay of the call will be accessible for approximately fourteen days following completion of the call by dialing (888) 566-0513 or (203) 369-3063. A replay will also be available on MannKind's website for fourteen days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA(R), an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at to which the company regularly posts copies of its press releases as well as additional information. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the SEC or posts certain other information to the website.

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MannKind Submits NDA for AFRESA for Treatment of Diabetes
2. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
3. MannKind Corporation to Hold Fourth Quarter Financial Results Conference Call on February 17, 2009
4. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
5. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
6. MannKind to Present at the Piper Jaffray 20th Annual Health Care Conference
7. MannKind to Present at the Rodman & Renshaw Annual Global Investment Conference
8. MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008
9. MannKind Unveils Proposed Trade Name at Dedication of Danbury Manufacturing Facility
10. MannKind to Present at the UBS Global Life Sciences Conference
11. MannKind Corporation Reports Second Quarter Financial Results
Post Your Comments:
(Date:6/23/2016)... SAN FRANCISCO , June 23, 2016   ... it has secured $1 million in debt financing from ... to ramp up automation and to advance its drug ... for its new facility. "SVB has been ... goes beyond the services a traditional bank would provide," ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample ... the Arkansas State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. ... said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding our capacity ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... 23, 2016 Andrew ... Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):